Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 09:01pm CEST

NEW BRUNSWICK, N.J., Jan. 3, 2018 /PRNewswire/ -- Nominations are now being accepted for the 2018 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 28, 2018 at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. A $200,000 cash prize will be awarded to the scientist or group of scientists receiving the Award.

The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), one of the most productive pharmaceutical scientists of the 20th century, who was responsible for breakthrough treatments in key disease areas including pain management, psychiatry, infectious disease and gastroenterology. Janssen founded Janssen Pharmaceutica, N.V., now part of the Johnson & Johnson Family of Companies (NYSE: JNJ).

"Behind every discovery that holds the promise for saving and improving lives are the scientists who pursue a vision and work tirelessly for many years to make it all possible," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "We are proud to honor the legacy of Dr. Paul by recognizing the outstanding researchers and champions of science who make a lasting impact on our world."

In 2017, the Dr. Paul Janssen Award recognized trailblazing scientist Douglas Wallace, Ph.D., of the Children's Hospital of Philadelphia, for pioneering the field of mitochondrial genetics and its application to the study of disease, aging, and patterns of human migration.

"Scientific research is crucial to advancing our understanding of the mechanisms underlying human health and disease," said David Julius, Ph.D., Professor and Chair of the Department of Physiology at the University of California, San Francisco, and Chair of the 2018 Dr. Paul Janssen Award selection committee. "The selection committee encourages nominations of scientists from academia, industry, government and scientific institutions around the world who champion science through the work they do everyday and exemplify the leadership and passion of Dr. Paul."

Previous Award winners include:

  • 2017 –  Douglas Wallace, Ph.D.
  • 2016 – Yoshinori Ohsumi, Ph.D., Nobel Laureate
  • 2015 – Bert Vogelstein, M.D.
  • 2014 – Emmanuelle Charpentier, Ph.D. and Jennifer Doudna, Ph.D.
  • 2013 – David Julius, Ph.D.
  • 2012 – Victor Ambros, Ph.D., and Gary Ruvkun, Ph.D.
  • 2011 – Napoleone Ferrara, M.D.
  • 2010 – Anthony S. Fauci, M.D. and Erik De Clercq, M.D., Ph.D.,
  • 2009– Axel Ullrich, Ph.D.
  • 2008 – Professor Marc Feldmann, FMedSci, FAA, FRS, Emeritus Professor and Sir Ravinder Maini, FRCP, FMedSci, FRS
  • 2006 – Craig Mello, Ph.D., Nobel Laureate

To learn more about past Dr. Paul Janssen Award winners, visit www.pauljanssenaward.com.

The 2018 Dr. Paul Janssen Award winner will be announced in spring 2018.

About The Dr. Paul Janssen Award for Biomedical Research
Established by Johnson & Johnson, The Dr. Paul Janssen Award salutes champions of science and the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Award is named after the scientist who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as "Dr. Paul," Janssen helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit www.pauljanssenaward.com for more information.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

 (PRNewsfoto/Johnson & Johnson)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/dr-paul-janssen-award-for-biomedical-research-issues-2018-call-for-nominations-to-celebrate-champions-of-science-300577115.html

SOURCE Johnson & Johnson


© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07:08pJOHNSON & JOHNSON : and picks Penn for research node
AQ
03:54pJOHNSON & JOHNSON REPORTS 2018 SECON : 2018 Second-Quarter Sales of $20.8 Billio..
AQ
03:23pJOHNSON & JOHNSON : and picks Penn for research-talk hub
AQ
02:38pJOHNSON & JOHNSON : Agloan-US Stocks Rebound on Tech, House Goods
AQ
02:20pCONFIDANTE OF TAIWAN PRESIDENT TO TA : reports
AQ
12:54pJOHNSON & JOHNSON : J&J stops Invokana trial early after success in kidney disea..
AQ
10:31aGENMAB : Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 201..
AQ
10:22aJOHNSON & JOHNSON : Janssen Announces U.S. FDA Approval of SYMTUZATM (D/C/F/TAF)..
PU
09:35aFetal gene therapy could treat neurodegenerative disease
AQ
08:48aJOHNSON & JOHNSON : J&J's Pharma Business Fuels Sales Growth -- WSJ
DJ
More news
News from SeekingAlpha
03:15pWhy Johnson & Johnson Is An Attractive Investment 
03:08pFDA committed to easing approval path for biosimilars 
02:14pJohnson & Johnson 2018 Q2 - Results - Earnings Call Slides 
11:23aJohnson & Johnson Raises Guidance, Now What? 
10:24aThis Dividend Aristocrat Just Posted 10% Sales And 15% EPS Growth - Is It A B..